Correlation of Homocysteine Level and Age in Patients with Ischemic Stroke

Muhammad Omer Sultan1, Umar Farooque2, Rafay Javed3

  • 1Internal Medicine, Jinnah Postgraduate Medical Center, Karachi, PAK.

Cureus
|May 29, 2020
PubMed

Insights

This study found no significant correlation between homocysteine levels and age in ischemic stroke patients. However, elevated homocysteine showed a significant linear relationship with diabetes mellitus and hypertension.

Area of Science:

  • Neurology
  • Cardiovascular Science
  • Metabolic Disorders

Background:

  • Hyperhomocysteinemia is linked to atherosclerosis and cardiovascular diseases.
  • Previous research on homocysteine levels, age, and stroke is controversial.
  • Investigating homocysteine's role in ischemic stroke is crucial.

Purpose of the Study:

  • To examine the relationship between homocysteine levels and age in ischemic stroke patients.
  • To explore the association of homocysteine with comorbidities like diabetes mellitus and hypertension.

Main Methods:

  • A cross-sectional study enrolled 178 ischemic stroke patients aged 40-75.
  • Demographics, smoking status, and homocysteine levels were recorded.
  • Pearson's correlation and chi-square tests were used for analysis.

Main Results:

  • No statistically significant correlation was found between homocysteine levels and age.
  • A significant linear relationship was observed between homocysteine levels and diabetes mellitus (DM) and hypertension (HTN).
  • Mean age was 55.60 ± 11.45 years; mean homocysteine was 14.61 ± 1.47.

Conclusions:

  • Homocysteine levels do not correlate with age in ischemic stroke patients.
  • Diabetes mellitus and hypertension are significantly associated with homocysteine levels.
  • Further large-scale studies are needed to clarify homocysteine's role in ischemic stroke and the benefits of screening, especially in the elderly with comorbidities.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
434
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
2.6K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
134
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
134
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
361
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
177